Ocumension Therapeutics announced that a clinical trial authorization for initiating a multi-regional phase III clinical trial (the "Phase III MRCT") in the United Kingdom for OT-101, a self-developed product of the Group, has recently been accepted by the Medicines and Healthcare products Regulatory Agency of the United Kingdom. Once the Phase III MRCT is approved, OT-101 is expected to be the world's first phase III MRCT of low concentration atropine and its analogues that includes Chinese population. OT-101 is a low-concentration atropine 0.01% eye drop developed by the Group to retard, or slow down, the progression of myopia in children and adolescents. The instability of low-concentration atropine solutions has long been a technical barrier for its commercialization. The Group developed a storage and delivery system to address low-concentration atropine solution's instability, and also conducted several rounds of tests on the system's reliability, closure integrity and sterility conditions.